The study aimed to assess the severity and progression of rectal toxicity in 134 prostate cancer patients who underwent transperineal brachytherapy and to identify contributing factors.
Findings revealed that 39% of patients experienced gastrointestinal toxicity, primarily Grade 1, with a median symptom duration of 6 months; only 2 patients showed severe Grade 3 toxicity.
Key factors linked to increased toxicity included the addition of external beam radiation, higher cancer stage, and Caucasian race, but most patients experienced mild symptoms overall.